DEVEX | The need for new products to address antibiotic-resistant infections is already staggering and growing, and there is great science being done to advance solutions to solve the crisis. But is the economics that are failing – not enough incentives and money to ensure that solutions being discovered and developed will actually reach the patients who need them. Organizations like CARB-X are supporting the early development of innovative products but there is a serious shortage of support for the more expensive later stages of development. “Let me tell you, the last thing we want to do is get these companies to sort of this … graduation stage, and then they fall off a cliff,” says Erin Duffy, CARB-X R&D Chief in this article written by Jenny Lei Ravelo, that examines the issues and also looks at some of the breakthrough diagnostics supported by CARB-X.